| Budget Amount *help |
¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Outline of Final Research Achievements |
Intervertebral disc disease (IVD) and osteoarthritis (OA) are the most common musculoskeletal diseases and numerous molecular mechanisms have been associated with these conditions. We identified c-fos/AP-1 as a molecule that shares pathological pathways in both of IVD and OA. Using newly developed specific inhibitor for the c-fos/AP-1, we demonstrated that the inhibitor mainly reduced expression of matrix-degrading enzymes, such as mmp-13 and adamts5 in disc cells, disc tissue, as well as in chondrocytes. Medication of the c-fos/AP-1 inhibitor to IVD and OA model animals demonstrated remarkable inhibitory effect on the progression of these conditions. Thus, therapeutic strategies targeting c-fos/AP-1 could become an important direction to treat both of IVD and OA.
|
